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Thick-filament sarcomeremutations are a common cause of hypertrophic cardiomyopathy (HCM), a disorder of heartmuscle thickening
associatedwith sudden cardiac death and heart failure, with unclearmechanisms.We engineered four isogenic induced pluripotent stem
cell (iPSC) models of b-myosin heavy chain andmyosin-binding protein C3mutations, and studied iPSC-derived cardiomyocytes in car-
diacmicrotissue assays that resemble cardiac architecture and biomechanics. All HCMmutations resulted in hypercontractility with pro-
longed relaxation kinetics in proportion to mutation pathogenicity, but not changes in calcium handling. RNA sequencing and expres-
sion studies of HCMmodels identified p53 activation, oxidative stress, and cytotoxicity induced bymetabolic stress that can be reversed
byp53genetic ablation.Ourfindings implicate hypercontractility as a direct consequenceof thick-filamentmutations, irrespectiveofmu-
tation localization, and the p53 pathway as a molecular marker of contraction stress and candidate therapeutic target for HCM patients.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a human disorder
that affects 1 in 500 individuals with uncertain mecha-
nisms (Maron et al., 1995). Patients with HCM are diag-
nosed by the presence of unexplained left ventricular
hypertrophy (LVH) with preserved systolic contractile
function (Ho et al., 2002). In young athletes, HCM mani-
fests as a common cause of sudden cardiac death; while,
in adults, HCM is associated with heart failure that may
progress to require cardiac transplantation (Gersh et al.,
2011b). Over the last few decades, the genetic basis of
HCM has been demonstrated by inheritance of autosomal
dominant mutations in components of the force-produc-
ing sarcomere (Maron et al., 2012). About two-thirds of
HCM patients harbor heterozygous mutations in one of
two sarcomere genes: myosin heavy chain b (MHC-b is en-
coded byMYH7) or myosin-binding protein C (cMyBP-C is
encoded byMYBPC3) (Maron et al., 2012). Alongwith titin,
MHC-b and cMyBP-C are located in the thick filament
where ATP hydrolysis by MHC-b is coupled to force gener-
ation through interactions with the actin-rich thin fila-
ment (Figure 1A). A prevailing model suggests that HCM
mutations alter cardiac force generation through dysregu-
lation of calcium handling (Ashrafian et al., 2011; Lan
et al., 2013).WhetherMYBPC3 andMYH7mutations result
in HCM by shared or heterogeneous mechanisms remains
undetermined.
Recent functional studies of thick-filament HCM muta-
tions in reconstituted sarcomere and cardiomyocyte assays
have supported both gain- and loss-of-force production
models of HCM pathogenesis, thus suggesting that
changes in force production may not be a shared conse-
quence of HCM mutations. For example, MYH7-R453C
(arginine 453 substituted with cysteine) increased while
MYH7-R403Q (arginine 403 substituted with glutamine)
decreased force production in reconstituted actomyosin
motility assays (Nag et al., 2015; Sommese et al., 2013).
Equally puzzling, contractile studies of single cardiomyo-
cytes from MYH6-R403Q+/– mouse models, which recapit-
ulate LVH and fibrosis in vivo (Geisterfer-Lowrance et al.,
1990), have produced similarly conflicting results for the
identical mouse model and strain (Chuan et al., 2012;
Kim et al., 1999). Human patient-specific induced pluripo-
tent stem cell (iPSC) HCM models of MYH7-R663H (argi-
nine 663 substituted with histidine) have recapitulated
some features of HCM including cellular enlargement
and altered calcium handling (Lan et al., 2013), but me-
chanical phenotypes of HCM iPSC models have not been
comprehensively studied.
The apparent difficulty in establishing the pathogenesis
of HCM has been attributed in part to: (1) multiprotein as-
sembly limitations that hinder sarcomere functional anal-
ysis, (2) mouse models that express distinct sarcomere
components compared with humans (e.g., MYH6 instead
ofMYH7), (3) the lack of isogenic iPSC-derived cardiomyo-
cyte cell lines to control for genetic and epigenetic varia-
tion, and (4) the absence of biomimetic 3D human cardiac
tissue functional assays. Here, we set out to address these
limitations by combining genetic engineering tools to
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Figure 1. Human iPSC-Derived CMT Models with Thick-Filament HCM Mutations Result in Hypercontractility
(A) A representation of the sarcomere is shown that includes thick-filament components myosin heavy chain b (MHC-b) (blue globular
heads connected to thin rods) and myosin-binding protein C (MYBPC3) (chain of light blue ovals); and thin-filament components actin
(gray ovals) and the troponin complex (orange ovals). Location of mutations are decorated on the crystal structures of MHC-b-S1 (blue
ribbon, left) and a domain of MYBPC3 (blue ribbon, right) (Fujii and Namba, 2017). Note: MHC-b-S1 is shown interacting with two actin
molecules (gray and pink ribbons) and a regulatory light chain (orange ribbon). For MYH7, R403Q is identified by a red R (1), and V606M is
denoted by a red V (2). For MYBPC3, the location of the truncation W792fs is denoted by a dashed line (3), and R502W is denoted by a
red R (4). Scale bars, 62.5 A˚ (MHC-b) and 31 A˚ (MYBPC3).
(B) Experimental outline of isogenic HCM model generation using the guide RNA (gRNA)/Cas9 complex and single-stranded oligodeox-
ynucleotide to introduce HCM mutations into a control iPSC line. iPSCs are then differentiated to produce iCMs that are combined with
fibroblasts and an extracellular matrix slurry for CMT production. Scale bar, 10 mm. White arrows depict direction of contraction. Scale bars,
25 mm (top panel) and 200 mm (bottom panel). Both tissue twitch force and resting tension are quantified as well as CMT sarcomere
structure by immunofluorescence.
(C) Maximum twitch force from CMTs generated from control, MYH7-V606M+/– and MYH7-R403Q+/– iCMs.
(D) Maximum twitch force from CMTs composed of control, MYBPC3+/, and MYBPC3-R502W+/– iCMs.
(E) Resting tension produced by HCM CMTs compared with controls.
(F and G) Quantification of calcium transients (DF/Fo) measured in HCM and control CMTs stained with Fluo-4 while pacing at 1 Hz (F). See
representative tracing in (G).
(legend continued on next page)
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generate a series of scarless MYH7 and MYBPC3 HCM mu-
tations in human isogenic iPSCs that are differentiated to
cardiomyocytes (iCMs) that express human sarcomere con-
tractile components. We generated 3D cardiac microtissues
(CMTs) (Figure 1B) to identify mechanical consequences of
HCM mutations in combination with molecular assays to
interrogate insights into HCM pathogenesis.
RESULTS
Generation of HCM iPSC and CMT Models Using
CRISPR/Cas9
We began by identifying two HCM mutations in MYH7,
R403Q and V606M (valine 606 substituted with methio-
nine), which cause autosomal dominant HCM in both hu-
mans (Geisterfer-Lowrance et al., 1990; Marian et al., 1995)
and mice (Blankenburg et al., 2014; Geisterfer-Lowrance
et al., 1996). Both mutations are located in subfragment 1
(S1) of MHC-b near the actin-interacting domain (Fig-
ure 1A), but R403Q leads to a more severe cardiomyopathy
compared with V606M (Blankenburg et al., 2014). Because
MHC-b physically interacts with MYBPC3 (Maron et al.,
2012), we hypothesized that these mutations could lead
to HCM by a shared mechanism.
We next selected a common pathogenic truncation mu-
tation in MYBPC3 (clinvar.com), a guanine insertion that
leads to tryptophan 792 substituted with valine followed
by a frameshift (Trp792ValfsX41; MYBPC3+/), and a
common pathogenic missense mutation, arginine 502
substituted with tryptophan (R502W) that is found in up
to 2.4% of HCM patients (Figure 1A) (Saltzman et al.,
2010).We generated scarless, isogenic iPSCmodels of these
four mutations with CRISPR technology using delivery of a
single optimized guide RNA, Cas9 nuclease, and a single-
stranded oligodeoxynucleotide repair template (Figure 1B;
Table S1). We chose an isogenic approach to focus our
investigation on the direct functional consequences of
the four thick-filament mutations, while controlling for
background epigenetic and genetic variation. To generate
the four iPSC models, we screened 1,111 clones by
Sanger sequencing (Table S1). After screening for off-target
genome-editing loci by sequencing (crispr.mit.edu) and
karyotype abnormalities by virtual karyotyping using
arrays (Table S2), we directly differentiated iPSCs (Lian
et al., 2013) followed by metabolic enrichment (Tohyama
et al., 2013) to generate purified iCMs. Finally, we com-
bined iCMswith tissue-forming fibroblasts and an extracel-
lular matrix slurry to generate a 3D CMTassay that recapit-
ulates native cardiac architecture and mechanics, which
has been adapted from prior assays applied to study
contractility phenotypes of dilated and PRKAG2 cardiomy-
opathy iPSC models (Boudou et al., 2012; Hinson et al.,
2015, 2016).
Thick-Filament HCM Mutations Result in
Hypercontractility
To study the mechanical consequences of MYH7 and
MYBPC3 mutations in a biomimetic context, we first opti-
mized our CMTassay (Hinson et al., 2015, 2016) to increase
sarcomere gene expression of thick-filament transcripts. In
particular, MYH7:MYH6 is upregulated in the developing
human heart (Wessels et al., 1991) and iCMs express fetal-
to neonatal-stage transcript levels. By increasing the size of
the microfabricated tissue gauges, including a proportional
increase in cantilever dimensions and spring constant (Fig-
ure S1A), we improved CMT durability from 4 to 10 days
(Figure S1B), which was associated with a 42% increase in
MYH7:MYH6 expression (Figure S1C, left panel) and
630% increase in cardiac troponin I (TNNI3) expression
(Figure S1C, right panel). We utilized this improved CMT
assay to study HCM mutations. For all CMT studies, we
measured contractility parameters on day 7 after tissue
compaction has completed and force production has pla-
teaued (Figure S1D).
CMTs generated from iCMs with MYH7-R403Q+/–
(Figure S1E) generated a 40.9-mN twitch force compared
with 21.7 mN in isogenic controls (Figure 1C). We then
tested whether the increased twitch force generated by
R403Q+/– was secondary to changes in sarcomere isoform
expression or clonal variation. TNNI3 expression (Yang
et al., 2014), a transcript marker that is related to cardio-
myocyte maturation, was unchanged (Figures S2A and
S2B) (Yang et al., 2014). Increased contraction force was
also similar between two independent R403Q+/– clones
(Figure S2C). Moreover, CMT cross-sectional area did not
differ between HCM mutations and isogenic controls (Fig-
ure S2D), which confirmed that HCM tissues were not hy-
percontractile secondary to increased CMT thickness. We
next tested whether CMT assays could predict pathoge-
nicity of MYH7 mutations by testing CMTs generated
from iCMs with the less-pathogenic MYH7 variant
V606M+/–, which is also located in the actin-binding
domain of S1 (Figure S1F). V606M+/– CMTs generated a
31.9-mN twitch force compared with 21.7 mN in isogenic
controls (Figure 1C), which was less than R403Q+/–. We
(H) Representative calcium transient tracing of control iCMs treated with verapamil or carrier control.
(I) Dependence of maximum twitch force generated by HCM and control CMTs from extracellular calcium concentration.
Significance assessed by ANOVA (C–F and I) (*all p < 0.05 and **all p < 0.001); data are means ± SEM (error bars) (C–I). Each data point
represents a single CMT (C–F and I) generated by at least three biological replicates by iPSC differentiation batch.
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concluded thatMYH7 variant pathogenicity positively cor-
relates with maximum contraction force in CMT assays for
the two mutations tested. We also generated two MYBPC3
mutant CMT models to compare with MYH7 models.
MYBPC3+/ and MYBPC3-R502W+/– CMTs generated a
41.0- and 42.9-mN twitch force compared with 21.7 mN in
isogenic controls, respectively (Figure 1D and Videos S1
and S2). Because sarcomere function also contributes to
twitch-independent contraction force, or resting tension,
we measured this parameter in CMTs. In parallel to twitch
force changes, resting tension was increased in all HCM
models except for MYH7-V606M+/– (Figure 1E). Because
V606M+/– results in a mild phenotype, we did not further
characterize this variant.
To characterize the molecular basis of HCM hypercon-
tractility, we measured both calcium transients and levels
in CMTs by optical imaging and calcium-dependent fluo-
rescent dyes. HCM-associated hypercontractility was not
related to changes in calcium delivery to the myofilament
as calcium transients were unaffected in all HCM muta-
tions tested (Figures 1F and 1G). This is distinct from
CMT treatment with verapamil, a voltage-gated calcium
channel blocker, which resulted in diminished CMT force
production in parallel to reduced calcium transients as ex-
pected (Figure 1H). Because the increase in resting tension
observed in HCM CMTs could be secondary to myofila-
ment activation due to increased resting calcium levels,
we stained iCMs with Indo-1 and measured both resting
and caffeine-induced activation. Indo-1 signal was un-
changed in HCMCMTs compared with controls at baseline
and after caffeine treatment (Figures S2E and S2F). Finally,
we tested CMT force production at low and high calcium
concentrations (1 and 3 mM) to address the dependence
of extracellular calcium on HCM hypercontractility. We
found that at both low (1 mM) and high (3 mM) calcium
levels, HCM CMTs compared with controls resulted in hy-
percontractility (Figure 1I). These data support a model
whereby thick-filament HCM mutations result in hyper-
contractility that is independent of variant localization,
myofilament calcium delivery, and extracellular calcium
levels.
We also measured HCM-associated contraction and
relaxation kinetics by quantifying maximum contraction
velocity, contraction time, and relaxation half-time across
all HCM mutations. Compared with controls, HCM CMTs
exhibited a 79%–121% increased maximum contraction
velocity (Figures 2A and 2B), but without changes in
contraction time (Figure 2C). Relaxation half-time (t1/2)
was prolonged (Figure 2D), which further supports that
impaired relaxation is a consequence of HCM thick-fila-
ment mutations, which has also been documented in
HCM patients (Ho et al., 2017). These kinetic changes are
distinct from kinetic changes induced by omecamtiv me-
carbil (Malik et al., 2011), a direct myosin activator that
prolongs contraction time. We conclude that HCM muta-
tions induce a state of hypercontractility that is distinct
from how omecamtiv mecarbil activates MHC-b through
stabilization of the lever arm (Planelles-Herrero et al.,
2017).
Reduction of Hypercontractility by Calcium Channel
Blockers and Direct Myosin Inhibitors
We generated CMTs from the severe HCM mutation
MYH7-R403Q+/–, and assessed changes in twitch force
and resting tension after treatment with two candidate
small molecules. We started by evaluating one of the
most commonly prescribed therapies for HCM patients,
the voltage-dependent L-type calcium channel blocker
A B C
D
Figure 2. Contraction and Relaxation Ki-
netics Are Altered by HCM Mutations
(A) Representative twitch force tracings
from MYH7-R403Q+/– CMT models compared
with isogenic controls.
(B–D) Normalized maximum contraction ve-
locity (B), contraction time (C), and relaxa-




Significance was assessed by ANOVA (B–D)
(*all p < 0.05 and **all p < 0.001); data are
means ± SEM (error bars) (A–D). Each data
point represents a single CMT (B–D) gener-
ated by at least three biological replicates by
iPSC differentiation batch.
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verapamil (Gersh et al., 2011a; Endoh and Blinks, 1988). In
accord with changes in calcium transients (Figure 1H), the
addition of verapamil reduced twitch tension by 31.7% in
R403Q+/– CMTs (Figure 3A). We also tested the direct
myosin inhibitor blebbistatin to assess whether myosin in-
hibitors may similarly reduce HCM-associated hypercon-
tractility in R403Q+/– CMTs. Since blebbistatin binds to
MHC-b distinct from residues near R403Q, and does not
interfere with actin-binding or actomyosin disassociation
(Kovacs et al., 2004), we hypothesized that this molecule
may also reduce twitch force. Similar to verapamil, blebbis-
tatin reduced twitch force by 35.3% (Figure 3B). Because
blebbistatin inhibits myosin by a calcium-independent
mechanism and resting calcium levels were not altered by
HCM mutations, we hypothesized that only blebbistatin
could normalize both twitch and resting tension induced
by HCMmutations. Indeed, blebbistatin but not verapamil
reduced resting tension by 10.2% (Figure 3C). These data
obtained from R403Q+/– CMTs suggest that therapeutic
agents that reduce both twitch and resting forces may be
more efficacious for HCM patients, which may explain
why verapamil has limited clinical efficacy in HCM pa-
tients (Sen-Chowdhry et al., 2016).
MYH7-R403Q+/– CMTs Exhibit Myofibrillar Disarray
and iCM Hypertrophy
To determine whether HCM mutations affect sarcomere
structure in CMTs, we fixed CMTs and stained sarcomeres
using antibodies to Z-disc protein alpha actinin with
DAPI co-stain (Figure 4A). We again focused on R403Q+/–
because this mutation is highly pathogenic in humans
and in our mechanical assays. Z disk analysis of R403Q+/–
tissues demonstrated increased Z disk angular dispersion
(Figures 4B and S3A), which is a measure of Z disk disarray.
This result is consistent withmyofibrillar disarray observed
in HCM patients (Bulkley et al., 1977). Sarcomere length
and cell number were not different (Figures S3B and S3C)
in R403Q+/– CMTs compared with isogenic controls. To
assess iCM size, we fixed and immunostained R403Q+/–
iCMs (Figure 4C) because the analysis of individual iCMs
is not feasible within our CMT assays. Single R403Q+/–
iCMs demonstrated increased iCM cell area (Figure 4D).
We next measured levels of candidate hypertrophy
signaling pathways including mitogen-activated protein
kinase pathways, AKT and CAMKII, as these have been
implicated in cardiomyocyte hypertrophy in vivo and in
iCMs (Hinson et al., 2015; Zhang et al., 2003). In propor-
tion to increased iCM cell area, lysates from R403Q+/–
iCMs had elevated levels of phosphorylated ERK2 and
AKT (Figures 4E–4G), but not p38, JNK, or CAMKII (Fig-
ure S3D). In summary, R403Q+/– mutations result in sarco-
mere disorganization in CMTassays, and iCMhypertrophy
in parallel with increased ERK2 and AKT signaling.
RNA Sequencing Identifies Activation of p53 Signaling
in HCM Models
To identify molecular mechanisms of HCM mutations, we
applied RNA sequencing to iCM samples from HCM
mutations (MYH7-R403Q+/–, MYBPC3+/, and MYBPC3-
R502W+/–) and compared the results with isogenic con-
trols. We started by analyzing the MYBPC3+/ mutation,
tryptophan-792-valine-fs, to determine howMYBPC3 trun-
cation mutations cause HCM. Consistent with nonsense-
mediated messenger RNA decay, transcripts from the
tryptophan-792-valine-fs allele were nearly absent com-
pared with wild-type transcripts (Figure 5A). This is in
contrast to the missense mutation R502W, which had no
evidence of degradation of mutant transcripts. In parallel
to changes in MYBPC3 transcript level, cMyBP-C protein
content was also reduced in MYBPC3+/ (Figures 5B and
5C) but not R502W+/– (Figures S4A and S4B) by immuno-
blotting iCM lysates with an antibody that recognizes the
A B C
Figure 3. Reduction of Hypercontractility in MYH7-R403Q+/– Tissues by Small Molecules
Representative tracings and percentage change in twitch force for MYH7-R403Q+/– CMTs treated with carrier control (black tracing)
compared with (A) verapamil (0.5 mM; red tracing) or (B) blebbistatin (10 mM; red tracing). (C) Comparison of the effects of verapamil and
blebbistatin on resting tension in MYH7-R403Q+/– CMTs. Significance was assessed by Student’s t test (A–C) (*all p < 0.05); data are
means ± SEM (error bars) (A–C). Each data point represents a single CMT (C) generated by at least three biological replicates by iPS
differentiation batch.
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amino terminus of cMyBP-C proximal to the frameshift
mutation. These data support a haploinsufficiency model
of HCM-associated MYBPC3 frameshift mutations, and
also that R502W is likely a loss-of-function missense
mutation.
Next, we analyzed iCM gene transcripts by unsupervised
principal-component analysis (PCA) to assess sample-to-
sample distances. All HCM samples clustered distinctly
from isogenic controls, while biological replicates within
the same genotype clustered closely (Figures 5D and 5E;
Table S3). Of note, gene components obtained from PC1
and PC2 include mitochondrial-encoded transcripts (MT-
TP, MT-ND6, MTATP6P1, MT-ND4L, MT-ATP8, MT-RNR1,
and MT-ND2), extracellular matrix-related transcripts
(COL3A1, FBN1, SULF1, BGN, and LGALS1), sarcomere
transcripts (ACTC1, MYL3, and MYL7), and p53-related
gene targets (CDKN1A and LINC01021) (Hunten et al.,
2015).
To better define the HCM-associated gene transcript pro-
gram, we analyzed differentially expressed transcripts that
were common to all HCM iCM models (Figure S4C; Table
S4). In accord with the close proximity of HCM samples
by PCA analysis, differentially expressed transcripts were
also highly shared among HCMmodels. Of 1,050 total up-
regulated transcripts, 320 were shared by at least two HCM
models, and of the 1,177 total downregulated transcripts,
Figure 4. CMT and iCM Structural and Molecular Signaling Changes in MYH7-R403Q+/– Models
(A) Representative confocal image of CMTs generated from MYH7-R403Q+/– and control iCMs and decorated with antibodies to cardiac
alpha actinin (green) and co-stained with DAPI (blue). Scale bar, 10 mm.
(B) Quantification of sarcomeric Z disk angular dispersion obtained from analysis of confocal regions of interest from CMTs decorated with
antibodies to alpha actinin.
(C) Representative confocal images of single MYH7-R403Q+/– and control iCMs decorated with antibodies to cardiac alpha actinin (green)
and co-stained with DAPI (blue). Scale bar, 10 mm.
(D) Quantification of MYH7-R403Q+/– and control iCM cell area from confocal images stained with alpha actinin.
(E–G) Representative immunoblots from MYH7-R403Q+/– and control iCM lysates probed with antibodies to phospho- and total ERK (note:
ERK2 is highly phosphorylated in iCM lysates) and phospho- and total AKT as well as GAPDH (loading control) (E). Normalized quanti-
fication of (F) phospho-AKT to total AKT and (G) phospho-ERK2 to total ERK2.
Significance was assessed by Student’s t test (B, D, F, and G) (*all p < 0.05); data are means ± SEM (error bars) (B, D, F, and G). Each data
point represents a single CMT (B), iCM (D), or sample generated from a batch of iCMs (F and G) generated by at least three biological
replicates by iPS differentiation batch.
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419 were shared by at least two HCMmodels. Of note, the
HCM phenotype did not correlate with expression of car-
diac chamber-specificmarkers such asmyosin light chain 7
(MYL7), myosin light chain 2 (MYL2), and potassium chan-
nel HCN4 (Figure S4D). We then used differential expres-
sion results to perform pathway analysis in HCM iCM
models using Ingenuity Pathway Analysis. Both p53 and
CDKN1A (p21) pathways were predicted to be highly acti-
vated in HCM iCMs (Figure 5F; Table S5) as prioritized by
activation Z score and p value of overlap. In parallel to tran-
script levels, p53 and p21 protein levels were increased in
HCM iCM lysates (Figures 5G–5I). In addition, fixed and
immunostained HCM CMTs also exhibited increased p53
staining within the nuclei of ACTN2+ iCMs (Figures 5J
and 5K). Unexpectedly, these results implicate altered p53
signaling as a common molecular consequence of thick-
filament HCM mutations.
HCM iCMs Exhibit a p53-Dependent Cytotoxicity
Induced by Metabolic Stress
To understand the role of elevated p53 signaling in HCM
iCM models, we first determined whether p53 activation
reflected increased iCM stress. We started by re-examining
RNA sequencing data for p53-dependent gene expression
changes that function in the regulation of cell death
including BBC3, BAX, and FAS. HCM iCMs have increased
expression of these transcripts relative to controls (Han
et al., 2001). We then tested whether HCM mutations re-
sulted in increased iCMdeath in normal growth conditions
(Figure S4E). We could identify no baseline change in iCM
death, which was also consistent with our observation that
CMT cell number and tissue cross-sectional area were not
altered by HCM mutations. We then considered whether
HCM iCMsmay bemore susceptible to cell stress. Informed
by the clinical observation that HCM patients have bio-en-
ergetic deficits in vivo (Crilley et al., 2003), as well as the
increased expression of mitochondrial gene transcripts in
HCM iCMs (Figure 5E), we measured iCM cell death
induced by metabolic stress from glucose removal that
has been used by others to induce energy stress (Jones
et al., 2005). We found that HCM iCMs exhibited elevated
cytotoxicity (Figure 6A) compared with controls, which
was associated with increased ADP:ATP (Figure 6B)—a
marker of metabolic stress. We next tested whether p53
knockdown by lentiCRISPR could rescue HCM-associated
cytotoxicity induced by metabolic stress. P53 knockdown
partially rescued HCM cytotoxicity induced by metabolic
stress (Figure 6C), and also resulted in reduced expression
of p53-target CDKN1A (Figure 6D).
To gain insights into molecular linkages between thick-
filament HCM mutations and p53 activation, we started
by measuring known regulators of p53, including DNA
damage (Lakin and Jackson, 1999) and oxidative stress
(Hwang et al., 2001). While the levels of phosphorylated
histone 2Amember X (Figure 6E), a marker of DNA damage
was not different between R403Q+/– iCMs compared
with controls, reactive oxygen species (ROS) levels were
increased over 3-fold (Figure 6F). Because ROS generation
is generated by respiring mitochondria, we also stained
iCMs withMitoSOX (Figure 6G) andMitoTracker dyes (Fig-
ure 6H) to quantify both mitochondrial-derived ROS and
mitochondrial content, respectively. Compared with con-
trols, HCM iCMs had higher mitochondrial-derived ROS
production and mitochondrial content. Finally, we tested
whether ROS inhibition by n-acetylcysteine (NAC) or p53
inhibition by pifithrin-a could normalize CMT force
Figure 5. RNA Sequencing of HCM and Isogenic Control iCMs
(A) By allele-specific analysis of gene transcripts obtained from isogenic control, MYBPC3+/, and MYBPC3-R502W+/– iCMs; MYBPC3
transcripts were quantified for control (wild-type [WT]; black bar) and mutant (red bar) alleles and shown as the proportion of total
MYBPC3 expression.
(B) Densitometry of immunoblots from protein lysates derived from control and MYBPC3+/ iCMs, and probed for MYBPC3 (note: truncated
MYBPC3 was not identified) and for protein loading with GAPDH.
(C) Representative immunoblot from (B).
(D) Principal-component analysis (PCA) of RNA transcripts from three biological replicates of isogenic control (purple triangles) and
MYBPC3+/ (blue circles), MYBPC3-R502W+/– (green circles), and MYH7-R403Q+/– iCMs (red circles).
(E) Hierarchical clustering of genes contributing to PC1 and PC2 from (D) and illustrated by heatmap (Table S2).
(F) Differentially expressed gene transcripts (log2FC > 0.3 or < –0.3 and false discovery rate < 0.1) were analyzed by pathway analysis using
Ingenuity Pathway Analysis and identified pathways (black and red dots) were organized by activation Z score and p value of overlap.
(G–I) Densitometry of immunoblots from control and HCM iCM protein lysates, normalized for protein loading (GAPDH) (G) and probed with
antibodies to p53 or (H) p21. See representative blots in (I).
(J and K) Quantification of iCM p53+ nuclei from confocal images of fixed CMTs immunostained with an antibody to p53 (red),
cardiomyocyte-specific ACTN2, and DAPI co-stain (J). See representative image in (K), arrowhead marks p53+ nuclei that co-stain with
ACTN2. Scale bar, 15 mm.
Significance (*p < 0.05 and **p < 0.001) was assessed by Fisher’s exact test (A), Student’s t test (B), or ANOVA (G, H, and J); and data are
means ± SEM (error bars) (B, G, H, and J). Each data point represents a sample generated from a batch of iCMs (B, D, E, G, and H) or single
CMT (J) generated by at least three biological replicates by iPS differentiation batch.
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production inHCMCMTs.While pifithrin-a treatment had
no influenceonCMTtwitch force,NACtreatment increased
twitch force similarly in HCM and control CMTs. These
data support that thick-filament HCM mutations result in
hypercontractility independent from p53 activation and
ROS production, and ROS is a negative regulator of CMT
twitch force. In summary,we conclude thatHCMmutations
result in a state of contraction stress characterized by oxida-
tive stress, p53 activation, and increased p53-dependent
cytotoxicity in the setting of metabolic stress.
DISCUSSION
The genetic basis of HCM, most commonly due to thick-
filament sarcomere mutations, was identified decades
ago, yet the mechanisms that link sarcomere gene muta-
tions with the HCM phenotype still remain unclear, in
part because of the lack of a robust human in vitro model
system to interrogate HCM pathogenesis. Here, we engi-
neered four human HCMmodels using CRISPR to generate
isogenic mutations in two of the most commonly mutated
sarcomere genes, andmeasured themechanical andmolec-
ular consequences of these variants in a biomimetic CMT
assay. We sought to determine the role of genetic heteroge-
neity on phenotypes identified in CMTand iCM functional
assays. Our study demonstrated a convergent model of
HCM pathogenesis whereby four thick-filament HCMmu-
tations, irrespective of mutation localization, induced a
state of hypercontractility due to both increased twitch
and resting tensions in parallel with delayed relaxation
kinetics. The increased resting tension has particular
A B C D
E F G H
Figure 6. HCM iCMs Exhibit a p53-Dependent Cytotoxicity with Metabolic Stress that Is Related to Increased Oxidative Stress
(A) Proportion of iCM death after 1 and 7 days of metabolic stress induced by growth in glucose-free medium.
(B) ADP:ATP for iCMs cultured in normal growth medium and after 24 hr in glucose-free medium.
(C) Change in iCM cytotoxicity measured by lactate dehydrogenase (LDH) release assay upon p53 genetic knockdown using lentiCRISPR
encoding two independent gRNAs that target the TP53 gene.
(D) qPCR analysis of CDKN1A normalized to ACTB obtained from cDNA libraries generated from MYH7-R403Q+/– iCMs transduced with
lentiCRISPR encoding two independent TP53 or non-targeted gRNAs.
(E) Quantification of phosphorylated H2A.X normalized to GAPDH using densitometry analysis of immunoblots from iCM lysates.
(F and G) Quantification of fluorescence (arbitrary units) using FACS analysis of iCMs stained with CellROX green (F) or MitoSOX red (G),
a mitochondrial-specific probe for reactive oxygen species.
(H) Quantification of fluorescence (arbitrary units) using FACS analysis of iCMs stained with MitoTracker green.
Significance (*p < 0.05 and **p < 0.001) was assessed by ANOVA (A) or Student’s t test (B–H); and data are means ± SEM (error bars)
(A–H). Each data point represents results obtained from a sample generated from a batch of iCMs (A–H) generated by at least three
biological replicates by iPS differentiation batch.
Stem Cell Reports j Vol. 12 j 71–83 j January 8, 2019 79
importance as this component of sarcomere contraction is
not affected by therapeutics that target only voltage-depen-
dent factors, such as the L-type calcium channel, which are
in clinical use for HCM patients, and provides a rationale
for the identification of therapeutics such as direct myosin
inhibitors that can reduce both resting and twitch contrac-
tion forces.
Our results of hypercontractility are in accord with
recent functional studies of HCM-associated thin-filament
mutant mouse models that support a sarcomere tension
model (Davis et al., 2016). HCM mutations in thin-fila-
ment genes were found to increase tension primarily by
increasingmyofilament calcium sensitivity, aswould be ex-
pected by changes in troponin complex function, while
our findings are consistent with a model whereby thick-
filament HCM mutations result in hypercontractility due
to intrinsic changes in sarcomere function independent
of changes in calcium delivery to the myofilament, and
at least in part independent from changes in myofilament
calcium sensitivity. Because thick-filament HCM muta-
tions consistently increased iCM size, our study cannot
exclude the contribution of iCMhypertrophy to hypercon-
tractility, especially in relation to myofilament calcium
sensitivity studies. Nonetheless, our model is also sup-
ported by recent biophysical studies of MHC-b and
cMyBP-C interactions that report changes in the accessi-
bility of myosin heads to generate force in the setting of
HCMmutations (Nag et al., 2017). Our inability to observe
previously described alterations in calcium handling may
be due to the nature of the variants studied, non-cell-
intrinsic mechanisms, or may be limited by the maturity
state of all iCM studies. We propose that the calcium
handling defects identified in other HCM studies are likely
indirect consequences of sarcomere mutations such as
induced by heart failure. In the future, it will be important
to test other thick-filament variants to identify potential
functional heterogeneity, as well as for comparison with
thin-filament CMT phenotypes.
Our study illuminates how HCM-associated hypercon-
tractility is maladaptive because it results in oxidative
stress, which is associated with reduced iCM viability in
the setting of metabolic stress in vitro. Energy imbalance
in HCM patients with significant LVH has been identified
in other studies (Jung et al., 1998), but to our knowledge
our study is the first to implicate an early, cell-intrinsic
metabolic vulnerability that results in altered cell survival.
While we did not observe an energy imbalance in HCM
iCMs in unstressed conditions, this may be secondary to
the fetal nature of iCM metabolism that favors glucose
rather than fatty acids for energy production. Our study
also provides a new in vitro assay for screening therapeutics
that modify HCM-associated iCM viability defects induced
by metabolic stress, such as through genetic and chemical
screens, which may provide new therapeutic targets for
HCM patients. Finally, we identify that HCM mutations
result in increased p53 signaling. While, to our knowledge,
p53 has been well studied in the context of cancer and
other disorders, it has not been implicated in HCM patho-
genesis and only recently implicated in regulating the car-
diac transcriptome (Mak et al., 2017). Notably, p53 genetic
ablation also protected against heart failure due to pressure
overload, but promoted age-associated cardiac dysfunction
(Mak et al., 2017). Our results suggest that p53 ablation
would be beneficial in HCM, and therefore molecular link-
ages between sarcomere variants, oxidative stress, and p53
activation, will need to be addressed in future studies
with potential therapeutic implications. Finally, our robust
genome-engineered platform using isogenic human
iPSCs combined with CMT assays demonstrates a robust
approach to interrogate HCM pathogenesis, test cardiomy-
opathy therapeutics, as well as classify sarcomere gene var-
iants of unknown significance.
EXPERIMENTAL PROCEDURES
iPSC Culture, iCM Differentiation, and Enrichment
The parental human iPSC line used for all studies was PGP1,
a normal control line obtained from the Coriell Institute
(GM23338) that has been described previously (Hinson et al.,
2015, 2016). This study was approved by the Jackson Laboratory
institutional review committee and institutional review board
approval was obtained as part of the Personal Genome Project.
All iPSC lines weremaintained onMatrigel (Corning)-coated tissue
culture plates in mTeSR1 medium (STEMCELL). iPSC lines were
screened for copy-number variants using Illumina SNP arrays as
described previously (Hinson et al., 2015). iPSCs were differenti-
ated to iCMs by sequential targeting of the WNT pathway as
described previously (Lian et al., 2013). iCMs were maintained in
RPMI with B27 supplement (Thermo Fisher Scientific) unless
otherwise noted. iCMs were enriched by metabolic selection by
previously described methods (Tohyama et al., 2013). On day 12
of iCM differentiation, beating iCMs were enriched by adding
4 mMDL-lactate (Sigma) in glucose-free DMEMmedium (Thermo
Fisher Scientific) for 48 hr. Following selection, enriched iCMs
were maintained in RPMI with B27 supplement. Only differentia-
tion batches with >90% troponin T2+ cells by fluorescence-
activated cell sorting (FACS) or estimated by morphology were
considered to be high purity for further assays. For all assays,
iCMs were studied on differentiation days 30–35. For all iCM and
CMT assays, at least biological triplicates (differentiation batches)
were studied.
CRISPR/Cas9 iPSC and iCM Gene Editing
Geneticmodificationswere generated using scarless iPSC clonal se-
lection by following protocols described previously (Hinson et al.,
2015). For MYH7 and MYBPC3 mutation generation, PGP1
iPSCs were electroporated with pCAG-eGFP-2A-CAS9 plasmid (ob-
tained from Addgene), a single-stranded mutation-specific 90mer
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oligonucleotide and an optimized guide RNA plasmid (Table S1).
After 48 hr, GFP+ iPSCs were sorted by flow cytometry FACS, clon-
ally expanded, and Sanger sequenced for genotyping. Guide RNAs
were designed and optimized using in silico methods that reduce
risk of off-target mutations (crispr.mit.edu). For MYH7 R403Q
gene editing, the corresponding region of MYH6 was sequenced
to verify no off-targetMYH6mutation. For lentiCRISPR (v2) exper-
iments (Addgene), protocols for guide RNA cloning and lentivirus
production were obtained from published methods, and a multi-
plicity of infection of 3 was used (Sanjana et al., 2014).
CMT Production and Force Measurements
CMTs were prepared as described previously (Hinson et al., 2015).
Polydimethylsiloxane (PDMS) (Sylgard 184 from Corning) canti-
lever devices were molded from SU-8 masters, with embedded
1-mM fluorescent microbeads (carboxylate FluoSpheres; Thermo
Fisher Scientific). PDMS tissue gauge substrates were treated with
0.2% pluronic F127 (Sigma) for 30 min to reduce cell-extracellular
matrix interactions. iCMsweredisassociatedusingtrypsindigestion
and mixed with stromal cells (human cardiac fibroblasts; single lot
obtained from Lonza), whichwere pre-treated with 10 mg/mLmito-
mycin C (Sigma) to prevent cell proliferation. The number of stro-
mal cells was 7% of the total cell population, which is the quantity
necessary for tissue compaction. A suspension of 1.3 3 106 cells
within reconstitution mixture containing 2.25 mg/mL collagen I
(BD Biosciences) and 0.5 mg/mL human fibrinogen (Sigma) was
added to the substrate.WemeasuredCMT functionat day7 to allow
for tissue compaction and stability of force generation. For quanti-
fying tissue forces, fluorescence images were taken at 25 Hz with
an Andor Dragonfly microscope (Andor iXon 888 EMCCD camera
withHCPL Fluotar 53 objectivemounted on aDMI8 [Leica]micro-
scope that was equipped with a fully enclosed live-cell environ-
mental chamber [Okolabs]). All tissues were biphasic stimulated at
1Hzwith aC-Pace EP stimulator (IonOptix) andplatinumwire elec-
trodes that were separated by 2 cm to the sides of the tissues tested.
The displacement of fluorescent microbeads was tracked using the
ParticleTracker plug-in in ImageJ (NIH). Displacement values were
analyzed in Excel (Microsoft) to compute twitch force (dynamic
force), resting tension, and kinetics. Resting tension was measured
bysubtracting the restingcantileverposition fromthecantileverpo-
sition prior to tissue generation. Cantilever spring constants were
computed using the empirically determined elastic modulus of
PDMS and the dimensions of the tissue gauge device as described
previously (Boudou et al., 2012). For small-molecule treatment,
CMTs were treated in Tyrode’s solution for 10 min with verapamil
(Tocris), blebbistatin (Tocris), pifithrin-a (Tocris), or NAC (Sigma)
prior to force measurements.
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Supplemental Experimental Procedures: 
Calcium (Ca2+) imaging using Fluo-4 AM and Indo-1 AM  
CMTs were loaded with 4 µM Fluo-4 AM (ThermoFisher) for 60 minutes at 37oC in Tyrode’s 
solution (140 mM NaCl, 5.4 mM KCL, 1mM MgCl2, 10mM glucose, 1.8 mM CaCl2 and 10mM 
HEPES pH 7.4 with NaOH). Following loading, tissues were washed three times in Tyrodes 
solution. Using a solid-state 50 mW 488 nm laser and GFP filter (emission 525+ 50nm), 
fluorescence intensities (F/Fo) were obtained while pacing tissues at 1 Hz. All images were 
captured at 30 fps on an Andor Dragonfly multimodal microscope. For each tissue, at least four 
regions of interest (ROIs) were analyzed for changes in Fluo-4 intensity, with the resting 
fluorescence value Fo determined by the average of the first five frames of the video. 
Background intensity was subtracted from all values. For iCM resting and caffeine-induced 
calcium quantification, single iCMs were disassociated from monolayer differentiation batches 
using accutase (ThermoFisher). Disassociated iCMs were loaded with 5 mM Indo-1 AM 
(ThermoFisher) in Tyrodes solution. ICMs were analyzed using a FACSymphony A5 analyzer 
(BD Biosciences). After excitation with a 60 mW 355 nm laser, Indo-1 signal ratios were 
determined using a 450nm dichroic mirror and BUF395 and BUV496 filters. To determine 
baseline calcium concentration, iCMs were analyzed for 20 seconds and the average Indo-1 ratio 
was obtained. To determine caffeine-induced calcium levels, a stock of 20 mM caffeine 
(ThermoFisher) in Tyrodes buffer was subsequently added to reach a 10 mM caffeine 
concentration, and maximum Indo-1 ratio was determined instantaneously.  
Immunofluorescence, protein quantification and sarcomere analysis 
Protein lysates obtained from iCMs were solubilized in RIPA buffer followed by western 
blotting. For analysis of MYBPC3 protein levels, an antibody that recognizes an n-terminal 
epitope of MYBPC3 protein was generously provided by Samantha Harris(Harris et al., 2002). 
All other antibodies used for immunoblotting include p53 (DO-7; ThermoFisher), p21 (#2947; 
Cell Signaling), phospho- and total ERK (#4370 and #4695; Cell Signaling), phospho- and total 
AKT (#2965 and #4691; Cell Signaling), phospho- and total p38 (#4511 and #8690; Cell 
Signaling), phospho- and total JNK (#4668 and #9252; Cell Signaling), phospho- and total 
CAMKII (#12716 and #4436; Cell Signaling), pH2A.X (#9718; Cell Signaling), GAPDH 
(#5174; Cell Signaling) and TNNI3 (#186820; ThermoFisher). For immunofluorescence, iCMs 
and CMTs were fixed with 4% paraformaldehyde (PFA) for 10 minutes, permeabilized and 
stained with antibodies to cardiac alpha actinin (#9465; Abcam) with DAPI co-stain. All 
immunofluorescence imaging was completed using a solid-state laser confocal microscope 
(Andor Dragonfly). CMT sarcomere analysis was done according to established methods(Bray et 
al., 2008). To determine z-disk anisotropy, CMTs were fixed with 4% PFA, permeabilized and 
immunostained with antibodies directed against Z-disk protein cardiac alpha actinin. Confocal 
images were obtained and analyzed using a modified ridge detection algorithm in ImageJ (NIH) 
to produce spatial maps of sarcomere Z-disks and the local orientation with respect to the x-axis 
of the image. For sarcomere length analysis, CMTs were relaxed in calcium-free buffer, fixed 
with 4% PFA, permeabilized and immunostained with antibodies directed against Z-disk protein 
cardiac alpha actinin. Confocal images were analyzed in ImageJ (NIH) using a Z-disk profile 
plot of greater than three regions of interest per CMT. ICM cell area was measured in iCMs that 
were cultured on glass coverslips, fixed with 4% PFA, permeabilized, and similarly 
immunostained. ICM cell area were measured using ImageJ.   
Cell viability, mitochondria and oxidative stress assays 
For metabolic stress assays, iCMs were cultured at sub-confluence in 6-well plates coated with 
fibronectin (10µg/ml; Corning) at a density of 100,000 cells/well. Prior to metabolic stress 
conditions, cells were maintained in RPMI with B27 supplement. To induce nutrient stress, cells 
were maintained in glucose-free DMEM media (ThermoFisher) with B27 supplement for up to 7 
days. To quantify iCM death, either LDH released from dead cells was analyzed from 
conditioned media using an LDH release assay (ThermoFisher), or viable cells were counted 
using live-cell imaging and a viability stain (MitoTracker Red CMXRos). ICM conditioned 
media was analyzed in a 96-well plate with a Synergy plate reader (BioTek) to quantify 
absorbance at 490 nm and 680 nm. For ADP/ATP ratios, 20,000 iCMs were plated on 
fibronectin-coated (10µg/ml; Corning) 96-well plates and analyzed by a bioluminescent 
ADP/ATP assay (Biovision). For mitochondrial content and reactive oxygen assays, iCMs were 
stained with MitoTracker Green (ThermoFisher)  or MitoSOX Red (ThermoFisher) in accord 
with manufacturer’s recommendations and single, disassociated iCMs were analyzed by FACS.  
RNA sequencing, quantitative PCR and computational analyses 
For iCM RNA sequencing experiments, total RNA was isolated from day 30-35 iCMs using 
Trizol (ThermoFisher). CDNA was constructed using Superscript III First-Strand synthesis 
(ThermoFisher). For each sample, total RNA from biological triplicates by differentiation batch 
was collected and sequenced. RNA sequencing libraries were generated using the TruSeq 
Stranded mRNA library preparation kit (Illumina). RNA sequencing libraries were sequenced on 
a HiSeq 2500 v4 SBS platform 2x100bp reads (Illumina). Sequences were aligned with 
STAR(Engstrom et al., 2013) to the hg38 human genome. For differential expression, DESeq2 
(Bioconductor) was used. Heatmap analysis and hierarchical clustering were performed using the 
Morpheus tool (Broad Institute). For quantitative PCR analysis, iCM total RNA was isolated and 
processed as above. Gene-specific PCR primers were identified from the literature or designed 
using Primer3 (see table S1 for primer sequences) and transcripts were quantified using Fast 
SYBR Green (Applied Biosystems) on a ViiA7 Real-Time PCR system (Applied Biosystems). 
RNA sequencing results files have been deposited in GEO (GSE113907). 
AFM Modulus Quantification 
To measure the elastic modulus of the PDMS used for tissue gauge production, indentation 
measurements were performed using Atomic Force Microscopy (AFM) (Asylum Research MFP-
3D, Santa Barbara, Ca). Using a colloidal silica spherical probe (AppNano FORT SiO2-A), a 
16x16 array of force-distance curves was acquired evenly spaced across a 2x2µm area for each 
measurement. Before and after these force-volume experiments, identical force-distance 
measurements on an incompressible surface were performed with a steel disk to calibrate the 
system sensitivity and to determine the spring constant for the force-transducing cantilever (1.75 
nN/nm of deflection, within the range of specifications for these commercial probes). All 256 
force-distance curves for each location studied were analyzed based on the Johnson-Kendall-
Roberts model of elastic contact. Such JKR mechanics accommodate large adhesion energies 
between an indenting probe and sample(Gupta et al., 2007; Huey, 2007), both expected and 
observed for these studies with PDMS. This incorporates the following experimental parameters: 
the indenter possesses a spherical tip geometry with a radius of 2.5 µm; the probe modulus 
appropriate for the colloidal silica sphere is 68.0 GPa; and this probe exhibits a Poisson ratio of 
0.19. A Poisson ratio of .33 is conventionally assumed for the specimen. For each of the samples, 
force-volume maps were completed at three representative locations. The average elastic 




Figure S1. CMT assay to study HCM models. (A) Design of cantilevers is shown with xyz 
dimensions. (B) New cantilever design and larger CMTs resulted in improved tissue durability as 
measured by tissue survival. (C) Sarcomere gene expression (left panel-MYH7 normalized to 
MYH6 and right panel-TNNI3 normalized to ACTB loading control) was measured using 
quantitative PCR between cDNA libraries produced from tissue samples of 400 µm and 1300 µm 
size. (D) Maximum twitch force plateaus for CMT models after day 5. (E) Ribbon diagram from 
electron cryomicroscopy structure of rabbit actomyosin rigor complex (myosin heavy chain S1 
(MHC-S1) colored blue and actin monomers colored gray and pink) showing location or R403Q 
(equivalent to R405 in rabbit MHC)(Fujii and Namba, 2017).  (F) Ribbon diagram from electron 
cryomicroscopy structure of rabbit actomyosin rigor complex showing location or V606M 
(equivalent to V608 in rabbit MHC)(Fujii and Namba, 2017).  Significance was assessed by 
Student’s t-test (B, C; *all p<0.05); data are means +/- SEM (error bars) (B, C and D). Scale bars 
are 29Å (E) and 32.8Å (F). Each data point represents a single CMT (B) or a sample generated 
from a batch of CMTs (C, D)  produced by at least three biological replicates by iPS 









































































































































Figure S2. Characterization of HCM CMT models. (A) TNNI3 normalized expression by 
RNA sequencing. (B) TNNI3 protein levels quantified by immunoblotting and densitometry 
analysis and normalized to GAPDH. (C) Maximum twitch force of CMTs generated from two 
independent clones of MYH7-R403Q+/- compared to isogenic controls. (D) Tissue cross-sectional 
area measured by confocal microscopy of four HCM models compared to isogenic controls. (E) 
Normalized basal and caffeine-induced calcium levels using FACS analysis to quantify Indo-1 
ratiometric signal for HCM and control iCMs.  (F) Representative FACS tracing of Indo-1 
ratiometric signal for isogenic control or MYH7-R403Q+/- iCMs (black arrow denotes time of 
caffeine stimulation). Significance (*p<0.05 and **p<0.001) was assessed by FDR (A), 
Student’s t-test (B) or ANOVA (A, C, D, and E); data are means +/- SEM (error bars) (A-E). 
Each data point represents a sample generated from a batch of CMTs (A, B) or a single CMT (C-








































































































































































































































































Figure S3. Sarcomere structure and functional analysis of HCM CMTs and iCMs. (A) 
Representative images of fixed CMTs immunostained with antibodies to cardiac alpha actinin to 
decorate sarcomere Z-disks (green) and analyzed by a modified ridge detection algorithm. 
Representative ridges shown in red with overlay confocal images (scale bar=10 µm). (B) 
Average sarcomere length obtained from confocal images of relaxed CMTs stained with 
antibodies to cardiac alpha actinin to decorate Z-disks. (C) CMT nuclei per high power field 
(HPF) of CMTs was quantified using confocal images of DAPI stained tissues. (D) 
Representative immunoblots from MYH7-R403Q+/- and control iCM lysates probed with 
antibodies to phospho- and total p38, phospho- and total JNK, phospho- and total CAMKII as 
well as GAPDH (loading control). Significance was assessed by Student’s t-test (B and C); data 
are means +/- SEM (error bars) (B and C). Each data point represents a sample generated from a 





















































































Figure S4. RNA sequencing of HCM models. (A) Quantification of MYBPC3 protein levels 
normalized to GAPDH by densitometry analysis of immunoblots of iCM lysates. (B) 
Representative MYBPC3 and GAPDH immunoblot used for (A). (C) Venn diagram to illustrate 
overlap in differential gene expression from RNA sequencing data obtained from three HCM 
models compared to isogenic controls (all FDR<0.10; log2FC>0.3 or <-0.3; see table S4). (D) 
Transcript levels of cardiac chamber-specific genes as quantified by RNA sequencing. (E) 
Cytotoxicity of iCMs cultured in growth media. Significance (p<0.05) was assessed by Student’s 
t-test (A, E) or FDR (C-D); data are means +/- SEM (error bars) (A, D and E). Each data point 
represents a sample generated from a batch of CMTs (A, C, D, E) produced by at least three 














































































































































Figure S5. CMT force production after inhibition of p53 or oxidative stress using small 
molecules. (A) RNA-seq and (B) quantitative PCR analysis of p53 transcriptional targets in 
HCM compared to isogenic control iCMs. (C) Quantification of CMT twitch force after 
treatment with N-acetyl cysteine (NAC) compared to carrier control for HCM iCMs and isogenic 
controls. (D) Quantification of CMT twitch force after treatment with p53 inhibitor pifithrin-α 
(PFT) compared to carrier control for HCM iCMs and isogenic controls. Significance (*p<0.05) 
was assessed by FDR (A), ANOVA (B) and Student’s t-test (C), and data are means +/- SEM 
(error bars) (A-C). Each data point represents a sample generated from a batch of CMTs (A, B) 















Captions for Tables S1-S5 
Table S1. CRISPR, PCR and other oligo sequences. (A) Sequences for gRNA backbone, 
mutation-specific gRNA recognition site, ssODN HR donor sequence and Sanger sequencing 
primers for genome engineering experiments involving the MYH7 and MYBPC3 genes. (B) 
Summary statistics of CRISPR/Cas9 genome editing efficiencies in HCM iPS models including 
homology-directed repair (HDR) and non-homology end-joining (NHEJ) repair efficiencies. (C) 
LentiCRISPR experiments targeting TP53 in iCMs including all gRNA sequences, 
oligonucleotides and qPCR primers for all gene expression studies. 
Table S2. CRISPR off-target and iPSc CNV results. (A) List of in silico off-target CRISPR 
genomic loci that were predicted by crispr.mit.edu and sequencing primers to verify genotypes.  
(B) IPSc CNV analysis by virtual karyotyping using SNP arrays. 
Table S3. Principle components from iCM RNA sequencing. Gene components and 
expression levels (fragments per million) of principle components 1 and 2 from fig.5D, E.  
Table S4. Differential expression from iCM RNA sequencing. Upregulated and 
downregulated gene transcripts from DESeq2 analysis of biological triplicates from MYBPC3+/-, 
MYBPC3-R502W+/- and MYH7-R403Q+/- compared to isogenic controls and organized by log2 
fold change (>0.3 or <-0.3) and adjusted p-value (FDR cutoff <0.1). 
Table S5. Pathway analysis from iCM RNA sequencing. Pathways enriched by Ingenuity 
Pathway Analysis of differential gene expression in HCM models compared to isogenic controls.  
 
Captions for Movies S1-S2 
Movie S1. Isogenic control CMT paced at 1Hz. Magnification- 5X. Scale bar=250µm. 
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